Elucidating the beneficial effects of gut microbiota-derived metabolites in treating hepatocellular carcinoma: an integrated network pharmacology, molecular docking, and single-cell sequencing analysis
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and the third leading cause of cancer-related mortality worldwide. While accumulating evidence has highlighted the beneficial effects of gut microbiota (GM)-derived metabolites in HCC treatment, the underlying mechanisms remain unclear. We retrieved...